Verena Briner - Novartis AG Insider

NVSN -- Mexico Stock  

MXN 1,570  8.70  0.55%

Non-Executive Independent Member of the Board

Dr. Verena A. Briner, M.D., serves as NonExecutive Independent Member of the Board of Novartis AG since 2013. Dr. Briner is professor of internal medicine at the Universitaet Basel, Switzerland, and chief medical officer and head of the department of medicine at the Lucerne Cantonal Hospital in Switzerland. She is a member of several medical and ethical institutions and commissions, including the board of the Foundation for the Development of Internal Medicine in Europe, the senate of the Swiss Academy of Medical Sciences, and the supervisory group for personalized medicine of the Centre for Technology Assessment TASWISS. She also is a member and former president of the Swiss Society of Internal Medicine
Age: 64  Executive Since 2013      
41 61 324 1111
Briner graduated from the Universitaet Basel with an M.D. in 1978, and has a specialized degree in internal medicine and nephrology from the Swiss Medical Association. She has received several prestigious scholarships and scientific grants, including the President?s Grant of the Society of General Internal Medicine in 2011, and is an honorary fellow of the American College of Physicians, the European Federation of Internal Medicine, the Polish Association of Internal Medicine, and the Swiss Society of General Internal Medicine. She was chief medical officer and department head at Swiss hospital; former president of Swiss medical society; member of various medical and ethical institutions and commissions.

Management Efficiency

The company has return on total asset (ROA) of 4.39 % which means that it generated profit of $4.39 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 10.33 % meaning that it generated $10.33 on every $100 dollars invested by stockholders.
The company has accumulated 28.53 B in total debt with debt to equity ratio (D/E) of 38.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Novartis AG has Current Ratio of 1.19 suggesting that it may not be capable to disburse its financial obligations in time and when they become due.

Similar Executives

Entity Summary

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland. Novartis AG operates under Drug Manufacturers - Major classification in Mexico and traded on Mexico Stock Exchange. It employs 121597 people.Novartis AG (NVSN) is traded on Mexico Stock Exchange in Mexico. It is located in Lichtstrasse 35 and employs 121,597 people.

Novartis AG Leadership Team

Joerg Reinhardt, Chairman, Ph.D
Ton Buechner, Director, MBA
Paul Hudson, CEO
Verena Briner, Executive
Brian McNamara, Executive
Michele Galen, Executive
Charles Sawyers, Executive, Ph.D
Steven Baert, Executive, MBA
Dimitri Azar, Director, MBA
Richard Francis, Executive
Frans Houten, Director
Nancy Andrews, Director, Ph.D
Enrico Vanni, Director, MBA
Pierre Landolt, Director
Elizabeth Doherty, Director
Andre Wyss, President
Bruno Strigini, CEO
Erwin Vanhaecke, Executive, Ph.D
Vasant Narasimhan, Executive
Michael Ball, CEO, MBA
Elizabeth Barrett, CEO, MBA
Jeffrey George, Executive, MBA
Mark Fishman, President, Ph.D
Charlotte PamerWieser, Executive
Shannon Klinger, Executive
Peter Kornicker, Executive, Ph.D
Andreas Planta, Director
Joseph Jimenez, CEO, MBA
Samir Shah, Executive
Ulrich Lehner, Chairman, MBA
William Winters, Executive, MBA
David Epstein, Executive, MBA
Ann Fudge, Director, MBA
Srikant Datar, Director, MBA
George Gunn, Executive, Ph.D
Paul Arkel, Executive
James Bradner, President
Felix Ehrat, Executive
Harry Kirsch, CFO
Andrin Oswald, Executive, Ph.D

Stock Performance Indicators

Current Sentiment - NVSN

Novartis AG Investor Sentiment
Macroaxis portfolio users are evenly split in their trading attitude regarding investing in Novartis AG. What is your trading attitude regarding investing in Novartis AG? Are you bullish or bearish?
50% Bullish
50% Bearish

Generate Optimal Portfolios

Align your risk and return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.